Skip navigation
Search
Sciety application settings
Home
Groups
Explore
Newsletter
About
Log In
Sign Up
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Raphael Ximenes
Alison E. Simmons
Gebremedhin B. Gebretekle
Austin Nam
Eva Wong
Marina I. Salvadori
Alyssa R. Golden
Beate Sander
Kyla J. Hildebrand
Matthew Tunis
Ashleigh R. Tuite
Read the full article
See related articles
Listed in
This article is not in any list yet, why not save it to one of your lists.
Log in to save this article
Abstract
No abstract available
Article activity feed
Version published to 10.1016/j.vaccine.2025.126985
Apr 1, 2025
Version published to 10.1101/2024.10.21.24315770 on medRxiv
Oct 22, 2024
Related articles
Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value
This article has 9 authors:
Katherine Hicks
Ziyi Xiao
Kelly Fust
Michele Kohli
Kyle Paret
Weijie Zhang
Maria de Pilar Martin Matos
Keya Joshi
Parinaz Ghaswalla
10-Year Analysis of the Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Disease
This article has 5 authors:
Galina L. Ignatova
Sergey N. Avdeev
Vladimir N. Antonov
Elena V. Blinova
Mikhail V. Osikov
Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for SARS-CoV-2 vaccines in 2024 in Austria
This article has 4 authors:
Uwe Riedmann
Martin Sprenger
John PA Ioannidis
Stefan Pilz
Site navigation links
Home
Groups
Explore
Newsletter
About
Log In
Sign Up